Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Farmers Insurance
Medtronic
Cantor Fitzgerald
McKesson
Harvard Business School
Baxter
Mallinckrodt
Boehringer Ingelheim
UBS

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 074270

« Back to Dashboard

NDA 074270 describes GEMFIBROZIL, which is a drug marketed by Mylan, Purepac Pharm, Apotex, Aurobindo Pharma Ltd, Cadila Pharms Ltd, Caribe Holdings, Chartwell Molecules, Hikma Pharms, Impax Pharms, Invagen Pharms, Northstar Hlthcare, Sandoz, Sun Pharm Inds Inc, Teva, and Watson Labs, and is included in eighteen NDAs. It is available from fifty-two suppliers. Additional details are available on the GEMFIBROZIL profile page.

The generic ingredient in GEMFIBROZIL is gemfibrozil. There are twenty drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the gemfibrozil profile page.
Summary for 074270
Tradename:GEMFIBROZIL
Applicant:Chartwell Molecules
Ingredient:gemfibrozil
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 074270
Medical Subject Heading (MeSH) Categories for 074270
Suppliers and Packaging for NDA: 074270
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
GEMFIBROZIL gemfibrozil TABLET;ORAL 074270 ANDA Blenheim Pharmacal, Inc. 10544-569 10544-569-90 90 TABLET, FILM COATED in 1 BOTTLE (10544-569-90)
GEMFIBROZIL gemfibrozil TABLET;ORAL 074270 ANDA PD-Rx Pharmaceuticals, Inc. 55289-411 55289-411-93 180 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (55289-411-93)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength600MG
Approval Date:Sep 27, 1993TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Moodys
McKesson
Chubb
Colorcon
Novartis
Johnson and Johnson
Chinese Patent Office
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot